Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1

Despite multiple studies demonstrating the importance of the anti-apoptotic protein Mcl-1 in tumor cell survival and treatment resistance, a clinically important inhibitor has yet to be developed. A recent study by Guo Wei and colleagues published in Cancer Cell has utilized a novel high-throughput...

Full description

Saved in:
Bibliographic Details
Published in:Genome medicine 2012-06, Vol.4 (6), p.53-53
Main Authors: Pfannenstiel, Lukas W, Demelash, Abeba, Gastman, Brian R
Format: Article
Language:English
Subjects:
Cancer
Research Highlight
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite multiple studies demonstrating the importance of the anti-apoptotic protein Mcl-1 in tumor cell survival and treatment resistance, a clinically important inhibitor has yet to be developed. A recent study by Guo Wei and colleagues published in Cancer Cell has utilized a novel high-throughput approach to identify compounds that act as transcriptional repressors of MCL1 expression. Their findings identified a number of candidate drugs to be tested for clinical relevance in human cancers dependent on MCL1 expression.
ISSN:1756-994X
1756-994X
DOI:10.1186/gm352